salima azahaf

salima azahaf

researcher

KU Leuven

Profile ID RP-003-7263 Joined 2025-12-18 1 article
0Connections
5
Total Views
1
Total Publications
23
Publication Views

Articles(1)

Authors: Salima Azahaf, Kaat Beunen, Nancy Van Wilder, Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, Xavier-Philippe Aers, Frank Nobels, Liesbeth Van Huffel, Joke Marlier, Dahae Lee, Joke Cuypers, Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter,

DOI: 10.1016/j.eclinm.2025.103106

Volume81
Issue103106
Pages103106
Abstract

Background A multicentre, randomised controlled trial (the CRISTAL trial), demonstrated the safety and efficacy of MiniMed™ 780G advanced hybrid closed loop (AHCL) therapy during pregnancy, showing improved glycaemic control overnight, less hypoglycaemia, and improved treatment satisfaction compared to standard insulin therapy (SoC, mainly open-loop insulin pump therapy). This study aimed to assess the cost-effectiveness of AHCL, which has a higher initial cost, compared to SoC in pregnant women with type 1 diabetes (T1D). Methods A decision tree model was developed to estimate the cost-effectiveness of AHCL compared to SoC in pregnant women with T1D, covering pregnancy to birth and postpartum hospital discharge (a time horizon of 28 weeks). Total costs per strategy (in 2024 euros, €) were calculated from a healthcare payer perspective. The base-case analysis derived prevalence of pregnancy complications and hospitalisations directly related to diabetes management from the CRISTAL trial. Uncertainty was analysed by exploring multiple scenarios and sensitivity analyses. Findings In the base-case analysis, the cost of using AHCL during pregnancy was estimated at €13,988.75 (95% CI: €12,240 to €16,062) compared to €14,221.33 (95% CI: €12,380 to €16,420) for SoC, indicating cost-savings of €232.57 per individual, alongside the demonstrated clinical benefits of AHCL. The primary cost driver was the AHCL device cost. This cost was offset by savings from shorter and less frequent hospital admissions (mainly due to severe hypoglycaemia and dysregulated diabetes) in the AHCL group compared to SoC. In our probabilistic sensitivity analysis, AHCL was dominant in 73% of the simulated cost-effectiveness pairs. Interpretation AHCL might be cost-saving compared to SoC for pregnant women with T1D. However, more robust data are needed to assess the potential impact of AHCL therapy on pregnancy and long-term health outcomes.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

No bio added yet.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Other Online Pages

Scholars in the same field

SD
Snehal dinesh borana
0 publications
CJ
Chandiran Joseph
0 publications
Jinu Sudhakaran
Kookmin University
6 publications
NA
Nalini Aswath
0 publications
SD
Shivani Datta
0 publications
VK
Vinay Kumar
0 publications
SR
Sharif Ratul Hassan
Northern University Bangladesh
0 publications
LT
LIKHITHA T G
0 publications
RS
R SANJAY
0 publications

Following

Nobody here yet.

Followers

Nobody here yet.

1 Publications